Results 41 to 50 of about 949,070 (290)
Marine Drugs, 2018 The ubiquitin-proteasome system (UPS) is a major proteolytic pathway that safeguards protein homeostasis. The main 26S proteasome consists of a 20S catalytic core proteasome and a 19S substrate recognition proteasome.
Xue-Hua Ling +4 more
doaj +1 more source
The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease
Biomolecules, 2022 Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases.
Ayse Seda Yazgili +2 more
doaj +1 more source
Dss1 Is a 26S Proteasome Ubiquitin Receptor [PDF]
, 2014 The ubiquitin-proteasome system is the major pathway for protein degradation in eukaryotic cells. Proteins to be degraded are conjugated to ubiquitin chains that act as recognition signals for the 26S proteasome.
Hardwick, Kevin G. +20 more
core +1 more source
Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
Pharmaceuticals, 2014 Multiple myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of neoplastic plasma cells. The use of proteasome inhibitors in the treatment of MM has led to significant improvements in outcomes.
Noah M. Merin, Kevin R. Kelly
doaj +1 more source
FoxM1 is a general target for proteasome inhibitors. [PDF]
PLoS ONE, 2009 Proteasome inhibitors are currently in the clinic or in clinical trials, but the mechanism of their anticancer activity is not completely understood. The oncogenic transcription factor FoxM1 is one of the most overexpressed genes in human tumors, while ...
Uppoor G Bhat +2 more
doaj +1 more source
[Retracted] Proteasome inhibitors in glioblastoma (Review)
Oncology Letters, 2017 Glioblastomas (GBM) are the tumors originating from the star shaped supportive cells in brain known as astrocytes. These tumors are highly cancerous as they have the ability to proliferate very quickly. New therapeutic strategies are being developed worldwide to fight against deadly GBM, which has median survival time of just 14 months.
Huang, Wen-Juan +2 more
openaire +5 more sources
FEBS Letters, EarlyView.Animals must match their growth rate to available nutrients. We show that in Drosophila larvae, the nutrient‐sensing TOR kinase controls growth by regulating levels of TFAM, a key regulator of mitochondrial function, in the adipose tissue. When nutrients are abundant, high TOR activity suppresses TFAM, lowering mitochondrial bioenergetic activity and ...
Shrivani Sriskanthadevan‐Pirahas +4 more
wiley +1 more source
Proteasome inhibitors as anti-cancer agents.
, 2000 The ubiquitin (Ub)-proteasome pathway is the major nonlysosomal pathway of proteolysis in human cells and accounts for the degradation of most short-lived, misfolded or damaged proteins.
Murray, Rachael, Norbury, Chris
core +1 more source
The microbiome in human skin aging
FEBS Letters, EarlyView.Age‐related skin changes encompass the well‐known visible phenotypic alterations, together with microbiome dysbiosis and a series of molecular aging hallmarks. These hallmarks characterize not only a fully stablished aged phenotype but also the skin aging process itself.
Manuel Huerta Arana +3 more
wiley +1 more source
Proteasome Inhibitors as a Potential Cause of Heart Failure [PDF]
, 2017 Key points • Proteasome inhibitors have become an important drug class in the treatment of multiple myeloma, and currently 3 have received regulatory approval.
Georgios Koulaouzidis +3 more
core +1 more source